关于《PARP抑制剂耐药机制及应对策略》的解读  

Interpretation of Understanding and overcoming resistance to PARP inhibitors in cancer therapy

作　　者：曾靖 尹如铁[1,2] ZENG Jing;YIN Rutie(Department of Obstetrics and Gynecology,West China Second University Hospital,Sichuan University,Chengdu,610041,Sichuan,China;Key Laboratory of Birth Defects and Related Diseases of Women and Children,Ministry cf Education,Chengdu,610041,Sichuan,China)

机构地区：[1]四川大学华西第二医院肿瘤放化疗科,四川成都610041 [2]出生缺陷与相关妇儿疾病教育部重点实验室,四川成都610041

出　　处：《肿瘤药学》2022年第4期422-427,共6页Anti-Tumor Pharmacy

基　　金：国家自然科学基金(81902649);四川省科学技术厅重点研发项目(19ZDYF);成都市科技局项目(2021-YF05-01725-SN)。

摘　　要：聚二磷酸腺苷核糖聚合酶(PARP)抑制剂在临床抗肿瘤治疗中得到广泛应用,然而大部分患者最终仍不可避免地发生耐药。PARP抑制剂的耐药机制复杂,克服耐药的策略众多,需要进行系统地梳理。因此,Dias等通过对其临床前及临床研究进行综述,揭示了多种PARP抑制剂的耐药机制,并提出克服耐药的策略。笔者对该文进行了解读,以期为临床医师及药师更深入认识PARP抑制剂的耐药机制及应对耐药策略提供一定的帮助。The poly ADP-ribose polymerase(PARP) inhibitors are widely used in anti-tumor therapy,but most patients will inevitably develop drug resistance.The mechanism of resistance to PARP inhibitors is complex,and there are many strategies to overcome drug resistance,which need to be systematically reviewed.Therefore,Dias et al.reviewed the preclinical and clinical studies of PARP inhibitors,revealed the resistance mechanisms of various PARP inhibitors,and discussed strategies to overcome resistance.Our interpretation of this review is expected to enhance the understanding of clinicians and pharmacists on the mechanisms of resistance to PARP inhibitors and the strategies for overcoming drug resistance,and to increase their attention to the future research.

关 键 词：PARP抑制剂 耐药机制 克服耐药策略 

分 类 号：R730.59[医药卫生—肿瘤]